UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000013782
Receipt number R000016086
Scientific Title Examination about the pharmacokinetics of the dexamethasone under the Fosaprepitant medication to the nausea and vomiting of an high emetic risk chemotherapy.
Date of disclosure of the study information 2014/04/22
Last modified on 2019/06/21 09:41:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Examination about the pharmacokinetics of the dexamethasone under the Fosaprepitant medication to the nausea and vomiting of an high emetic risk chemotherapy.

Acronym

PROEMEND PK

Scientific Title

Examination about the pharmacokinetics of the dexamethasone under the Fosaprepitant medication to the nausea and vomiting of an high emetic risk chemotherapy.

Scientific Title:Acronym

PROEMEND PK

Region

Japan


Condition

Condition

Inoperable advanced/recurrence Gastric Cancer or Esophageal Cancer or Colorectal Cancer

Classification by specialty

Gastroenterology Hematology and clinical oncology Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Examination about the pharmacokinetics of the dexamethasone under the Fosaprepitant medication to the nausea and vomiting of an high emetic risk chemotherapy.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

* Blood concentration of dexamethasone

Key secondary outcomes

* Frequency of vomiting
* Severity of nausea
* Grading of appetite
* Used amount of per-request medication


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Group A:
* 1st course: Palonosetron 0.75mg i.v. on 1st day+Aprepitant 150mg i.v. on 1st day+Dexamethasone 9.9mg i.v. on 1st day, 6.6mg i.v. on 2nd day and 3rd day.
* 2nd course: Palonosetron 0.75mg i.v. on 1st day+Aprepitant 150mg i.v. on 1st day+Dexamethasone 9.9mg i.v. on 1st day, 6.6mg i.v. on 2nd day and 13.2mg i.v. on 3rd day.

Interventions/Control_2

Group B:
* 1st course: Palonosetron 0.75mg i.v. on 1st day+Aprepitant 150mg i.v. on 1st day+Dexamethasone 9.9mg i.v. on 1st day, 6.6mg i.v. on 2nd day and 13.2mg i.v. on 3rd day.
* 2nd course: Palonosetron 0.75mg i.v. on 1st day+Aprepitant 150mg i.v. on 1st day+Dexamethasone 9.9mg i.v. on 1st day, 6.6mg i.v. on 2nd day and 3rd day.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Patients who receive the first cycle of chemotherapy with high emetic risk chemotherapy.
(2) Performance Status (ECOG)=0-2

Key exclusion criteria

(1) Patient who is taking Pimozide.
(2) Patient who has severe liver failure or renal failure.
(3) Patient who had been treated with one moderate risk emetogenic antitumour drug according to the 2014 National Comprehensive Cancer Network Clinical Practice Guidelines.
(4) Patient who has vomited or provoked nausea in the 24 hours prior to start of chemotherapy.
(5) Patient who is considered inappropriate as a target patient by a physician-in-charge.

Target sample size

12


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masahiro Goto

Organization

Osaka Medical College Hospital

Division name

Cancer Chemotherapy Center

Zip code


Address

2-7 Daigaku-machi, Takatsuki City, Osaka, Japan

TEL

072-683-1221

Email

in2030@osaka-med.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Masahiro Goto

Organization

Osaka Medical College Hospital

Division name

Cancer Chemotherapy Center

Zip code


Address

2-7 Daigaku-machi, Takatsuki-City, Osaka, Japan

TEL

072-683-1221

Homepage URL


Email

in2030@osaka-med.ac.jp


Sponsor or person

Institute

Osaka Medical College Hospital

Institute

Department

Personal name



Funding Source

Organization

Osaka Medical College Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

大阪医科大学附属病院


Other administrative information

Date of disclosure of the study information

2014 Year 04 Month 22 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled

12

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 11 Month 25 Day

Date of IRB

2014 Year 03 Month 03 Day

Anticipated trial start date

2014 Year 04 Month 01 Day

Last follow-up date

2018 Year 07 Month 20 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 04 Month 22 Day

Last modified on

2019 Year 06 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016086


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name